MBX Biosciences Inc. Comm... (MBX)
NASDAQ: MBX
· Real-Time Price · USD
16.69
-0.06 (-0.36%)
At close: Oct 03, 2025, 3:59 PM
16.57
-0.72%
After-hours: Oct 03, 2025, 06:44 PM EDT
-0.36% (1D)
| Bid | 12.62 |
| Market Cap | 560.67M |
| Revenue (ttm) | 222K |
| Net Income (ttm) | -77.02M |
| EPS (ttm) | -6.38 |
| PE Ratio (ttm) | -2.62 |
| Forward PE | -5.78 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 21.17 |
| Volume | 1,674,843 |
| Avg. Volume (20D) | 1,097,601 |
| Open | 16.74 |
| Previous Close | 16.75 |
| Day's Range | 16.47 - 17.63 |
| 52-Week Range | 4.81 - 27.50 |
| Beta | 0.81 |
| Ex-Dividend Date | n/a |
Analyst Forecast
According to 0 analyst ratings, the average rating for MBX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 week ago
-13.78%
MBX Biosciences shares are trading lower after the...
Unlock content with
Pro Subscription
1 week ago
+100%
MBX Biosciences shares are trading higher after the company announced once-weekly Canvuparatide achieved the primary endpoint in a Phase 2 trial.
1 week ago · seekingalpha.com
MBX Biosciences Looks A Buy As Hypoparathyroidism Data Wows MarketMBX Biosciences surged after canvuparatide's Phase 2 data showed strong efficacy and safety in hypoparathyroidism, addressing a significant unmet need. MBX's lead candidate outperformed placebo and co...
1 month ago · fool.com
Mbx Biosciences (MBX) Q2 Loss Widens 22%Mbx Biosciences (MBX) Q2 Loss Widens 22%